Primary care for the declining cancer survivor

,; ,; ,

Applied Evidence

Primary care for the declining cancer survivor

J Fam Pract. 2019 October;68(8):448-450,452-455

PDF Download

References

1. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2019-2021. www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2019-2021.pdf. Accessed September 4, 2019.

2. Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer. 2008;112(11 suppl):2577-2592.

3. National Comprehensive Cancer Network. NCCN Guidelines Version 2. 2019. Palliative Care. www.nccn.org/professionals/physician_gls/pdf/palliative.pdf. (Must register an account for access.) Accessed September 4, 2019.

4. American Cancer Society. New CoC accreditation standards gain strong support. www.facs.org/media/press-releases/2011/coc-standards0811. Accessed September 11, 2019.

5. Lupu D; American Academy of Hospice and Palliative Medicine Workforce Task Force. Estimate of current hospice and palliative medicine physician workforce shortage. J Pain Symptom Manage. 2010;40:899-911.

6. Lupu D, Quigley L, Mehfoud N, et al. The growing demand for hospice and palliative medicine physicians: will the supply keep up? J Pain Symptom Manage. 2018;55:1216-1223.

7. Rabow MW, Dahlin C, Calton B, et al. New frontiers in outpatient palliative care for patients with cancer. Cancer Control. 2015;22:465-474.

8. Haun MW, Estel S, Rücker G, et al. Early palliative care for adults with advanced cancer. Cochrane Database of Syst Rev. 2017:CD01129.

9. Buss MK, Rock LK, McCarthy EP. Understanding palliative care and hospice: a review for primary care providers. Mayo Clin Proc. 2017;92:280-286.

10. Hui D. Definition of supportive care: does the semantic matter? Curr Opin Oncol. 2014;26:372-379.

11. Simmons CPL, McMillan DC, McWilliams K, et al. Prognostic tools in patients with advanced cancer: a systematic review. J Pain Symptom Manage. 2017;53:962-970.

12. Lakin JR, Robinson MG, Bernacki RE, et al. Estimating 1-year mortality for high-risk primary care patients using the “surprise” question. JAMA Int Med. 2016;176:1863-1865.

13. Walczak A, Henselmans I, Tattersall MH, et al. A qualitative analysis of responses to a question prompt list and prognosis and end-of-life care discussion prompts delivered in a communication support program. Psychoonchology. 2015;24:287-293.

14. Yamaguchi T, Maeda I, Hatano Y, et al. Effects of end-of-life discussions on the mental health of bereaved family members and quality of patient death and care. J Pain Symptom Manage. 2017;54:17-26.

15. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, caregiver bereavement adjustment. JAMA. 2008;300:1665-1673.

16. Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007;34:94-104.

17. Gao W, Bennett MI, Stark D, et al. Psychological distress in cancer from survivorship to end of life: prevalence, associated factors and clinical implications. Eur J Cancer. 2010;46:2036-2044.

18. Scott IA, Gray LC, Martin JH, et al. Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. Evid Based Med. 2013;18:121-124.

19. Gramling R, Fiscella K, Xing G, et al. Determinants of patient-oncologist prognostic discordance in advanced cancer. JAMA Oncol. 2016;2:1421-1426.

20. Epstein AS, Prigerson HG, O’Reilly EM, et al. Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. J Clin Oncol. 2016;34:2398-2403.

21. Weeks JC, Cook EF, O’Day SJ, et al. Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA. 1998;279:1709-1714.

22. Myers J. Improving the quality of end-of-life discussions. Curr Opin Support Palliat Care. 2015;9:72-76.

23. Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioids. Ann Oncolog. 2016;27:1107-1115.

24. National Hospice and Palliative Care Organization. NHPCO Facts and Figures. 2018. www.nhpco.org/wp-content/uploads/2019/07/2018_NHPCO_Facts_Figures.pdf. Accessed September 24, 2019.

25. Meier EA, Gallegos JV, Thomas LP, et al. Defining a good death (successful dying): literature review and a call for research and public dialogue. Am J Geriatr Psychiatry. 2016;24:261-271.

26. Morden NE, Chang CH, Jacobson JO, et al. End-of-life care for Medicare beneficiaries with cancer is highly intensive overall and varies widely. Health Aff (Millwood). 2012;31:786-796.

27. Centers for Medicare & Medicaid Services. Medicare Hospice Benefit Facts. www.cgsmedicare.com/hhh/education/materials/pdf/Medicare_Hospice_Benefit_Facts.pdf. Accessed September 11, 2019.

28. Centers for Medicare & Medicaid Services. Medicare Hospice Benefits. www.medicare.gov/pubs/pdf/02154-medicare-hospice-benefits.pdf. Accessed September 11, 2019.

29. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437-1449.

30. Greco MT, Roberto A, Corli O, et al. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol. 2014;32:4149-4154.

31. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Recomm Rep. 2016;65:1-49.

32. Davis MP, Mehta Z. Opioids and chronic pain: where is the balance? Curr Oncol Rep. 2016;18:71.

33. Leppert W, Zajaczkowska R, Wordliczek J, et al. Pathophysiology and clinical characteristics of pain in most common locations in cancer patients. J Physiol Pharmacol. 2016;67:787-799.

34. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-173.

35. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456-2473.

36. Jones JA, Lutz ST, Chow E. et al. Palliative radiotherapy at the end of life: a critical review. CA Cancer J Clin. 2014;64:296-310.

37. Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1:778-784.

38. Kongsgaard U, Kaasa S, Dale O, et al. Palliative treatment of cancer-related pain. 2005. www.ncbi.nlm.nih.gov/books/NBK464794/. Accessed September 24, 2019.

39. Sathornviriyapong A, Nagaviroj K, Anothaisintawee T. The association between different opioid doses and the survival of advanced cancer patients receiving palliative care. BMC Palliat Care. 2016;15:95.

40. Steindal SA, Bredal IS. Sørbye LW, et al. Pain control at the end of life: a comparative study of hospitalized cancer and noncancer patients. Scand J Caring Sci. 2011;25:771-779.

41. Maltoni M, Setola E. Palliative sedation in patients with cancer. Cancer Control. 2015;22:433-441.

42. Cooper C, Burden ST, Cheng H, et al. Understanding and managing cancer-related weight loss and anorexia: insights from a systematic review of qualitative research. J Cachexia Sarcopenia Muscle. 2015;6:99-111.

43. Ruiz Garcia V, LÓpez-Briz E, Carbonell Sanchis R, et al. Megesterol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;28:CD004310.

44. Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387-2396.

45. Poulsen JL, Nilsson M, Brock C, et al. The impact of opioid treatment on regional gastrointestinal transit. J Neurogastroenterol Motil. 2016;22:282-291.

46. Pergolizzi JV, Raffa RB, Pappagallo M, et al. Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. Patient Prefer Adherence. 2017;11:107-119.

47. Walsh D, Davis M, Ripamonti C, et al. 2016 updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer. 2017;25:333-340.

48. Mücke M, Mochamat, Cuhls H, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev. 2015(5):CD006788.

49. Escalante CP, Meyers C, Reuben JM, et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J. 2014;20:8-14.

50. Hovey E, de Souza P, Marx G, et al. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer. 2014;22:1233-1242.

51. Hosker CM, Bennett MI. Delirium and agitation at the end of life. BMJ. 2016;353:i3085.

52. Mercantonio ER, Flacker JM, Wright RJ, et al. Reducing delirium after hip fracture: a randomized trial. J Am Geriatr Soc. 2001;49:516-522.

53. Casarett DJ, Inouye SK. Diagnosis and management of delirium near the end of life. Ann Int Med. 2001;135:32-40.

54. Breitbart W, Alici Y. Agitation and delirium at the end of life: “We couldn’t manage him." JAMA. 2008;300:2898-2910.

55. Candy B, Jackson KC, Jones L, et al. Drug therapy for delirium in terminally ill patients. Cochrane Database Syst Rev. 2012;11:CD004770.

56. Bascom PB, Bordley JL, Lawton AJ. High-dose neuroleptics and neuroleptic rotation for agitated delirium near the end of life. Am J Hosp Palliat Med. 2014;31:808-811.

57. Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol. 2012;30:1378-1383.

58. Albert RH. End-of-life care: managing common symptoms. Am Fam Physician. 2017;95:356-361.

59. Arenella C. Artificial nutrition and hydration at the end of life: beneficial or harmful? https://americanhospice.org/caregiving/artificial-nutrition-and-hydration-at-the-end-of-life-beneficial-or-harmful/ Accessed September 11, 2019.

60. Booth S, Moffat C, Burkin J, et al. Nonpharmacological interventions for breathlessness. Curr Opinion Support Pall Care. 2011;5:77-86.

61. Barnes H, McDonald J, Smallwood N, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016(3)CD011008.

62. Lim RB. End-of-life care in patients with advanced lung cancer. Ther Adv Resp Dis. 2016;10:455-467.

63. Kreher M. Symptom control at the end of life. Med Clin North Am. 2016;100:1111-1122.

64. Baralatei FT, Ackerman RJ. Care of patients at the end of life: management of nonpain symptoms. FP Essent. 2016;447:18-24.

65. Protus BM, Grauer PA, Kimbrel JM. Evaluation of atropine 1% ophthalmic solution administered sublingual for the management of terminal respiratory secretions. Am J Hosp Palliat Med. 2013;30:388-392.

Delirium can be treated with antipsychotics; haloperidol has been most frequently studied.⁵⁴ Antipsychotics are effective at reducing agitation but not at restoring cognition.⁵⁵ Case reports suggest that use of atypical antipsychotics can be beneficial if adverse effects limit haloperidol dosing.⁵⁶ Agitated delirium is the most frequent indication for palliative sedation.⁵⁷

Dyspnea. In the last weeks, days, or hours of life, dyspnea is common and often distressing. Dyspnea appears to be multifactorial, worsened by poor control of secretions, airway hyperactivity, and lung pathologies.⁵⁸ Intravenous hydration may unintentionally exacerbate dyspnea. Hospice providers generally discourage intravenous hydration because relative dehydration reduces terminal respiratory secretions (“death rattle”) and increases patient comfort.⁵⁹

Honest conversations, with best- and worst-case scenarios, are important to patients and families and should occur while the patient is well enough to participate and set goals.

Some simple nonpharmacologic interventions have benefit. Oxygen is commonly employed, although multiple studies show no benefit over room air.⁵⁹ Directing a handheld fan at the face does reduce dyspnea, likely by activation of the maxillary branch of the trigeminal nerve.⁶⁰

Opioids effectively treat dyspnea near the end of life with oral and parenteral dosing, but the evidence does not support nebulized opioids.⁶¹ Opioid doses required to treat dyspnea are less than those for pain and do not cause significant respiratory depression.⁶² If a patient taking opioids experiences dyspnea, a 25% dose increase is recommended.⁶³

Reversible causes of delirium include uncontrolled pain, medication adverse effects, and urinary and fecal retention.

Anticholinergic medications can improve excessive airway secretions associated with dyspnea. Glycopyrrolate causes less delirium because it does not cross the blood-brain barrier, while scopolamine patches have reduced anticholinergic adverse effects, but effects are delayed until 12 hours after patch placement.⁶⁴ Atropine eye drops given sublingually were effective in a small study.⁶⁵

Continue to: Palliative sedation